Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Monte Rosa Therapeutics (NASDAQ:GLUE) and maintained a $16 price target.
June 28, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Monte Rosa Therapeutics and maintained a $16 price target.
The reiteration of an Overweight rating and the maintenance of a $16 price target by a reputable analyst can boost investor confidence in Monte Rosa Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100